Eisai Korea (CEO Ko Hong-Byung)’s annual sales exceeded $200 billion. Operating profit, which has been steadily increasing along with sales, also surpassed $30 billion.
According to Eisai’s report of audit (June 30th), Eisai Korea made $209.6 billion in annual sales.
Eisai Korea recorded steady growth for the past three years since 2016 and made about $200 billion sales in 2018 by expanding insurance coverage of drugs with Lenvima, Symbenda, Tysabri, and Tecfidera.
Although Eisai Korea surpassed $200 billion by expanding its sales by $10 billion, the growth slowed significantly to 5.9 %.
The growth was stagnant, but the operating profits constantly exceeded $30 billion, and the rate of operating profits have risen to 15%.
Eisai Korea’s operating profit fell slightly from $16.1 billion in 2015 to $15.9 billion in 2016 but increased sharply thereafter.
The operating profit surpassed $20 billion in 2017 with $23.6 billion and exceeded $32 billion in 2019 from $29 billion in 2018. The size of the operating profit has doubled in about four years.
